Diltiazem HCl Injectable Drug Recalled for Sterility Assurance Failure
Nephron Sterile Compounding Center is recalling Diltiazem HCl injectable due to lack of sterility assurance. The FDA Class II recall affects 4,743 bottles distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for an injectable medication. No illnesses, injuries, or deaths are reported in the source. Per the severity rubric, this scores 3 (High) as a risk-of-harm product (injectable with potential for serious infections if contaminated) where injury has not yet been reported. Class II status without reported harm does not meet the threshold for Score 4 (Severe).
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (125 mL single-dose bottles). The affected lot is DS2053, expiration date February 27, 2023, with approximately 4,743 bottles distributed nationwide.
The FDA determined that this lot lacks assurance of sterility. Sterility is critical for injectable medications to prevent potentially serious infections.
Healthcare facilities and pharmacies that received product from lot DS2053 should identify any remaining inventory and follow appropriate quarantine procedures. Patients or individuals who received injections from this batch should consult their healthcare provider.
The recalled product
- Product
- Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-997-15.
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable / Intravenous
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: DS2053
- Exp. 2/27/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27